We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

37 hedge funds and large institutions have $205M invested in Y-mAbs Therapeutics in 2018 Q3 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

22.42% more ownership

Funds ownership: 0% → 22.42% (+22%)

Holders
37
Holders Change
+37
Holders Change %
–
% of All Funds
0.85%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
37
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SI
Sofinnova Investments
California
+$53.5M
2
SCM
Scopia Capital Management
New York
+$40.4M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$31.3M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$9.9M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$8.26M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
TAM
26
Tiverton Asset Management
Delaware
$348K +$333K +13,080 New
GCP
27
GSA Capital Partners
United Kingdom
$266K +$254K +10,000 New
FCM
28
Flinton Capital Management
Pennsylvania
$236K +$226K +8,874 New
TAM
29
Tyers Asset Management
Texas
$194K +$186K +7,308 New
NA
30
Neuburgh Advisers
California
$153K +$146K +5,742 New
Point72 Asset Management
31
Point72 Asset Management
Connecticut
$133K +$127K +5,000 New
MCIM
32
Meadow Creek Investment Management
Georgia
$111K +$106K +4,176 New
PHK
33
Point72 Hong Kong
Hong Kong
$86K +$82.7K +3,252 New
RCM
34
Riverhead Capital Management
Delaware
$63K +$60.5K +2,380 New
CSS
35
Cubist Systematic Strategies
Connecticut
$55K +$52.9K +2,082 New
CCA
36
Catalyst Capital Advisors
New York
$13K +$12.7K +500 New
Bank of America
37
Bank of America
North Carolina
$5K +$4.86K +191 New
Morgan Stanley
38
Morgan Stanley
New York
$3K +$2.54K +100 New
1
2

YMAB Hedge Fund Activity: Q3 2018 in Review

37 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q3 2018, worth a combined $205M.

Buyers outnumbered sellers: 37 funds opened new YMAB positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Sofinnova Investments, opening a new position worth an estimated $53.5M.

  • 37 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q3 2018, up from 0 in Q2 2018.
  • Funds reported $205M of Y-mAbs Therapeutics stock for Q3 2018.
  • 37 funds opened new Y-mAbs Therapeutics positions in Q3 2018 and 0 closed out, a net change of +37 holders.
  • The largest Y-mAbs Therapeutics buyer in Q3 2018 was Sofinnova Investments, an estimated $53.5M added.

Based on aggregated 13F filings for Q3 2018.